Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to
Poolbeg Pharma PLC (AIM:POLB) Positive Initial Data Analysis in POLB 001 Trial
Early data readout indicates a successful LPS human challenge trial
China’s great migration, first day of “chun yun” kicks-off under shadow of COVID
China marked Saturday the beginning of “Chun Yun”, the 40-day period for Lunar New Year travel in China. This was pre-pandemic the largest annual migration of people worldwide.
China in talks with Pfizer to create generic Covid drug
Three sources confirmed to Reuters that China is currently in negotiations with Pfizer Inc for a license that will allow Chinese drugmakers to produce and distribute a generic version of
Omega Diagnostics Gp (AIM:ODX) US expansion update
Maiden US Laboratory FoodPrint® installation,
hVIVO PLC (AIM:HVO) £5.2m RSV contract and Notice of Trading update
£5.2m RSV human challenge study contract with global biotechnology company in Asia Pacific and Notice of Trading Update
Many Chinese return to normal activity after COVID infection
People in China’s major cities of Beijing, Shanghai, and Wuhan braved the cold to resume regular activity Monday. They were optimistic about the economic recovery of more people who have
Is 2023 HVivo And Harland & Wolff Year
Stock markets in the UK are either heading into a recession or already are. Many investors are concerned about what the future holds for them.
Trader’s Cafe with Zak Mir: Stocks For 2023 Countdown 20 to Number 1
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
Share Talk Holiday Digest Review: GGP, HELD, GWMO, BOIL, ANGS, HARL, PREM, AVCT, MARU, ALK, GCAT, KOD, CRCL, ALL & FCM.
A brief rundown of Charles Archer’s Top 15 small-cap shares to consider for 2023.
4d Pharma PLC (AIM:DDDD) Update on Administration and Suspension of Trading
Leeds, UK – December 30, 2022 – 4D pharma plc (AIM: DDDD) (in administration), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived